We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 7.60 | 0.53% | 1,443.60 | 710,626 | 14:03:26 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,443.40 | 1,443.80 | 1,457.80 | 1,437.20 | 1,437.20 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 34.91B | 14.96B | 3.6522 | 3.94 | 58.99B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:03:44 | O | 2,400 | 1,443.2746 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/12/2023 | 15:00 | UKREG | GSK PLC Total Voting Rights |
| 30/11/2023 | 09:00 | UKREG | GSK PLC Block Listing Application |
| 29/11/2023 | 15:23 | UKREG | GSK PLC Holding(s) in Company |
| 27/11/2023 | 09:00 | ALNC |  GSK announces positive results from Blenrep phase 3 blood cancer trial |
| 27/11/2023 | 07:00 | UKREG | GSK PLC GSK announces positive DREAMM-7 headline results |
| 21/11/2023 | 15:30 | UKREG | GSK PLC Director/PDMR Shareholding |
| 21/11/2023 | 11:52 | ALNC | GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024 |
| 15/11/2023 | 15:00 | UKREG | GSK PLC Block listing Interim Review |
| 13/11/2023 | 15:30 | UKREG | GSK PLC Director/PDMR Shareholding |
| 13/11/2023 | 09:47 | ALNC | GSK hails momelotinib opinion from European Medicines Agency committee |
Gsk (GSK) Share Charts1 Year Gsk Chart |
|
1 Month Gsk Chart |
Intraday Gsk Chart |
| Smart Money! GSK is a large holding in the following funds: | ||
| Fund | Percentage of Fund | Last Updated |
| JPMORGAN CLAVERHOUSE INVESTMENT TRUST PLC | 2.90% | 2023-10-31 |
| BMO UK HIGH INCOME TRUST PLC | 6.62% | 2022-05-31 |
| Date | Time | Title | Posts |
|---|---|---|---|
| 01/12/2023 | 11:55 | Glaxosmithkline - The recovery | 32,584 |
| 24/9/2023 | 20:42 | GLAXOSMITHKLINE WITH CHARTS & NEWS | 188 |
| 07/6/2023 | 07:22 | GlazoSmithKline - News & Information | 138 |
| 17/4/2023 | 18:25 | Gsk zantac | 1 |
| 28/2/2023 | 16:35 | GSK launched Shingrix, which has a far superior shingles prevention effect | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:03:46 | 1,443.60 | 265 | 3,825.54 | AT |
| 14:03:46 | 1,443.40 | 101 | 1,457.83 | AT |
| 14:03:46 | 1,443.40 | 185 | 2,670.29 | AT |
| 14:03:44 | 1,443.27 | 2,400 | 34,638.59 | O |
| 14:03:24 | 1,443.60 | 229 | 3,305.84 | AT |
| Top Posts |
|---|
Posted at 04/12/2023 08:20 by Gsk Daily Update Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,436p.Gsk currently has 4,095,026,002 shares in issue. The market capitalisation of Gsk is £58,992,944,585. Gsk has a price to earnings ratio (PE ratio) of 3.94. This morning GSK shares opened at 1,437.20p |
Posted at 29/11/2023 08:37 by tradermichael You'd think so. However, it didn't seem to benefit the GSK price when the pound dropped from 1.27 to 1.23 ..... ;0) |
Posted at 15/11/2023 12:02 by anhar For most of its existence, sentiment towards GSK has been very poor. Doesn’t look like that’s changing anytime soon. Definitely frustrating though.I've held since dinosaurs roamed and your comment is accurate though I wouldnt say the poor sentiment has been "for most of its existence". Hard to see now but long ago there was a time whn the share was quite highly regarded as shown by a yield of only about 2%. However the poor sentiment of more recent years is not baseless. For some time the company has delivered poor financial results, not helped by increasingly monstrous debt. So even an upturn in its fortunes will take a while to impress cynical institutional investors who I think have long held, and rightly, a less than optimistic opinion of the company. The best thing imo they have done recently is the HLN demerger and I continue to hold my allocation. I'm primarily an income investor but if I look at the capital performance over the decades, it's only because HLN is showing a profit that my combined holding is showing a tiny profit over the original cost of old GSK after all these years, as new GSK is showing a loss over the demerger adjusted price. As for income, which is my reason for holding equities at all, that has also been trashed following the demerger. I'm guessing that sooner or later this crock GSK will probably be turned round, something that management has singularly failed to do for many years. Not sure I'll live that long though... |
Posted at 15/11/2023 09:37 by abdullla GSK share price going against the rise in the Ftse,getting ready for the double drop tomorrow due to X-div |
Posted at 17/10/2023 17:39 by pj84 From the above:-... "The board now expects GSK to generate sales growth of between 8pc and 10pc and adjusted operating profit and earnings per share growth in the range of 11pc to 13pc and 14pc to 17pc respectively. On each occasion GSK nudged up growth estimates by a couple of percentage points." ... "GSK’s aim is to double sales of Shingrix to £4bn by 2026 and last week’s exclusive strategic agreement with China’s largest vaccine firm, Chongqing Zhifei Biological Products, to co-promote the product is a big step in that direction." ... "Yet GSK trades at barely 11 times forecast earnings, with a dividend yield near 4pc. The earnings multiple represents a clear discount to rivals such as AstraZeneca, Switzerland’s Roche, tipped yesterday in this column’s online version, and America’s Bristol-Myers Squibb, which trade on 30, 15 and 14 times earnings respectively. The shares would also look cheap were GSK to meet its own long-term growth targets, reaffirmed alongside the interim results. It is committed to generating compound trend sales growth of more than 5pc a year and compound adjusted operating profit growth of more than 10pc a year, as profit margins expand from the 30pc recorded in the first six months of 2023. GSK could look cheap as and when the legal clouds lift." |
Posted at 17/10/2023 13:40 by anhar Correct TM. GSK is an outstanding example of all those styles:Growth - after about a million years of holding, I'm up just 12.6% on original cost. This includes my HLN demerger shares. Not that I'm a growth player but that's the fact. Failed. Income - This is my style. Divis were static for eight years at 80p for old GSK from 2014-2021 though admittedly there was a 20p special back in 2016. Following that payout paralysis, after the demerger the combined divis from new GSK and HLN were slashed. Failed. Value - hard to see that GSK is underpriced with all that debt. Net debt at 30/6/23 was £18bn against net assets of £12bn and NAV is most certainly not above the share price. Failed. So indeed GSK has something to offer these three approaches and it's ultra reliable. It fails all three. |
Posted at 11/10/2023 06:38 by garycook GSK PLC11 October 2023 Issued: 11 October 2023, London UK Statement: Zantac (ranitidine) litigation GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement in the Cantlay/Harper case filed in California state court. The case, which was set to begin trial on 13 November 2023, will be dismissed. The company has also settled the three remaining breast cancer bellwether cases in California. GSK will be dismissed from these cases, removing all related pre-trial hearings for the company. The settlements reflect the Company's desire to avoid the distraction related to protracted litigation. GSK does not admit any liability in the settlements and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases. |
Posted at 18/9/2023 09:48 by anhar On the demerger I split the original cost in my records of old GSK, that I'd held for decades, by the stated ratio to arrive at the revised book cost of new GSK and HLN.What's interesting is that now, my gain on HLN, which of course I've held only since the dem, is roughly the same in cash terms as the gain on new GSK, yet HLN cost is far smaller at about 18% of my combined original cost, with new GSK about 82%. The effect is that HLN is up about 37% since the dem whilst new GSK is up only about 8% following the recent price rises. Another result of the much higher percentage gain on HLN is its increased proportion of the combined present value of the two holdings, now about HLN 21% and new GSK 79%. I conclude that hanging on to HLN, from a capital viewpoint, was the right thing to do. But I'm not claiming any prescience here, it's just that the default position in my income port is to do nothing with most corporate actions and I've found over the decades that demergers in particular are normally beneficial over time. I'm only an income player so all this is academic for me, but nevertheless interesting to observe. As I've mentioned, the effect of all this on the divis, my reason for investing in shares at all, has unfortunately been negative. |
Posted at 29/8/2023 09:23 by anhar POR: What slashed divi?Afaiaa, the divi was adjusted to take into account the recent splitting off of HLN. Add the two divis together and they probably add up to the pre-split gsk divi. Not 100% sure, but in any case, no one sensible would say the divi has been 'slashed', imv. If you can't stand the heat etc. Oh, you already have left the kitchen. I think you are referring to another reader, I have not left but as a long term hold divi investor continue to retain both GSK and HLN. But the slashed divi comment was mine. I suggest you should check before referring to factual matters because I think you are wrong. Here's why old GSK 2021 divi 80.00p new GSK 2022 divi 57.75p HLN 2022 divi 2.4p Thus the total for the two for 2022 of 60.15p is below the old GSK 80p for 2021 by 24.8%. I'd call that slashed and so you are incorrect to claim that they "probably add up to the pre-split gsk divi" or that "no one sensible would say the divi has been 'slashed', imv." Another way to look at it, which avoids the potential distortions of the share adjustments, is not at the divis per share but to compare the total cash income received by an investor like me who continued to hold throughout the demerger, with no voluntary shareholding changes. Without a doubt my income has been "slashed". HLN paid only the final divi for 2022 and will likely pay both an interim and final for 2023 but it remains very unlikely that even then, the total income from both for 2023 will match that from old GSK for 2021. |
Posted at 23/8/2023 09:26 by anhar Indeed TM, I'm not complaining, you were right this time, saved by the excellent China shingles news I expect.After holdnig for decades though, GSK remains a divi slashing, debt guzzling, poorly profitable pile of wossname. I'm purely an income investor but if I look at the share price including my HLN shares from the demerger, I'm up only very slightly on capital value, 3-4%. Not great after all that time and it has frequently shown a loss. After shovelling so much of their debt on to HLN, I thought GSK might be cured of their debt addiction but no such luck. It has since swollen, assisted by a big US acq at a huge premium, way more than is normal for acqs of listed companies. As a very long term income investor, I hang on to both shares in the hope that divis will grow as I'm loathe to sell any share from my port. It has to be really down the toilet before I dump, typically with suspended divis and no clear hope of a near term resumption. It hasn't come to that with GSK - yet - as it still pays a divi. But servicing their gigantic debt burden is a brake on divi growth. |
Posted at 29/6/2023 13:45 by tradermichael ssued: 28 June 2023, London UKGSK completes acquisition of BELLUS Health GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC. In connection with the closing of the Arrangement, BELLUS also announced the cancellation of its annual shareholder meeting, which was scheduled for 30 June 2023. Luke Miels, Chief Commercial Officer, GSK said: "The acquisition of BELLUS is highly synergistic with GSK's expertise in respiratory medicines and is further supported by GSK's leading R&D, manufacturing, and commercialisation capabilities. We are now focused on progressing camlipixant through phase III trials to offer a therapeutic option for RCC patients as soon as possible." Following the anticipated regulatory approval and launch of camlipixant, the acquisition is expected to be accretive to adjusted EPS from 2027 and has the potential to deliver significant sales through 2031 and beyond. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
